The Manufacturers Life Insurance Company raised its stake in Ra Pharmaceuticals Inc (NASDAQ:RARX) by 30.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,860 shares of the company’s stock after buying an additional 2,543 shares during the quarter. The Manufacturers Life Insurance Company ‘s holdings in Ra Pharmaceuticals were worth $204,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in Ra Pharmaceuticals by 28.3% in the 2nd quarter. Vanguard Group Inc. now owns 346,602 shares of the company’s stock valued at $6,496,000 after buying an additional 76,349 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Ra Pharmaceuticals by 70.3% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 21,800 shares of the company’s stock valued at $409,000 after buying an additional 9,000 shares during the period. Nationwide Fund Advisors increased its stake in Ra Pharmaceuticals by 1,078.4% in the 2nd quarter. Nationwide Fund Advisors now owns 32,842 shares of the company’s stock valued at $615,000 after buying an additional 30,055 shares during the period. JPMorgan Chase & Co. increased its stake in Ra Pharmaceuticals by 33.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 199,900 shares of the company’s stock valued at $3,746,000 after buying an additional 50,432 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in Ra Pharmaceuticals by 57.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 37,932 shares of the company’s stock valued at $711,000 after buying an additional 13,881 shares during the period. Hedge funds and other institutional investors own 69.64% of the company’s stock.

Several research analysts have weighed in on the stock. Royal Bank Of Canada reiterated a “buy” rating and issued a $18.00 price objective on shares of Ra Pharmaceuticals in a research note on Tuesday, December 5th. BMO Capital Markets upped their price objective on shares of Ra Pharmaceuticals in a research note on Tuesday, December 5th. Zacks Investment Research lowered shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 15th. Credit Suisse Group upped their price objective on shares of Ra Pharmaceuticals from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, November 10th. Finally, Jefferies Group reiterated a “buy” rating and issued a $25.00 price objective on shares of Ra Pharmaceuticals in a research note on Thursday, September 28th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $23.20.

Ra Pharmaceuticals Inc (NASDAQ:RARX) opened at $7.51 on Monday. Ra Pharmaceuticals Inc has a 12 month low of $7.15 and a 12 month high of $27.84.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.06). sell-side analysts anticipate that Ra Pharmaceuticals Inc will post -2.46 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “The Manufacturers Life Insurance Company Grows Holdings in Ra Pharmaceuticals Inc (RARX)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/the-manufacturers-life-insurance-company-grows-holdings-in-ra-pharmaceuticals-inc-rarx/1756977.html.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Institutional Ownership by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.